
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES131
One RCT251 reported that at 12 months there were no significant changes from baseline in HbA1c, FPG, BMI, triglycerides and high-density lipoprotein cholesterol (HDL-C) in patients treated with telmisartan or nifedipine gastrointestinal therapeutic system (nifedipine GITS) and there were no  significant differences in any of these parameters between treatments. Level 1+

[@Fern_ndez_2001]

